Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer

    loading  Checking for direct PDF access through Ovid


Topotecan is active in advanced or metastatic cervical cancer even in patients who have received prior cisplatin-based chemotherapy, although hematologic toxicity has limited its use. Studies in cervical cancer have utilized topotecan administered on days 1–5 of each 21- or 28-day cycle. Alternative schedules, such as weekly schemes, have proven to ameliorate hematological toxicity. The objective of this study was to analyze the results of weekly topotecan as second- or third-line therapy in advanced or metastatic cervical cancer. Eligible patients had histologically confirmed cervical carcinoma, measurable disease, and at least one prior chemotherapy regimen. Topotecan was administered at a dose of 3 mg/m2 (maximum, 5 mg per dose) diluted in 250 ml of normal saline in a 30-min infusion weekly for every 28 days. We assessed response and toxicity. Twenty-two patients entered this study. Eighteen patients were evaluable for toxicity and response. Patients received a mean 3.5 courses (range, 1–6 courses). No complete or partial responses were observed; five (27.7%) patients exhibited disease stabilization as maximum response (two in irradiated sites, and three in lung/mediastinum). Median progression-free interval was 3.5 months (95% confidence interval [CI]: 3.75–4 months) and median overall survival was 7 months (95% CI: 6–8.7 months). Weekly topotecan administration achieved disease stabilization in 27.7% of heavily pre-treated patients. The achievement could be of worth in this setting in which disease prolongation is desirable.

Related Topics

    loading  Loading Related Articles